Cancer stem cells (CSCs) drive recurrence and resistance, evading standard therapies through iron-rich metabolism and ...

A first-in-human phase 1 trial of the Fc-enhanced CD40 agonist antibody 2141-V11 has shown striking results: six of 12 ...

Researchers have identified RUNX1C, an RNA isoform that drives chemoresistance in acute myeloid leukemia (AML). The study, ...

The FDA has granted accelerated approval to Wegovy® (semaglutide) as the first treatment for MASH with moderate-to-advanced ...

Researchers have developed a novel cancer therapy using Salmonella typhimurium to deliver an oncolytic virus directly into ...

A novel mRNA-based vaccine encoding tumor-specific neoantigens significantly enhanced anti-PD-1 therapy in gastric cancer ...

FDA approved Papzimeos (zopapogene imadenovec), the first-in-class, non-replicating adenoviral vector-based immunotherapy, ...

ONCOLife as a cutting-edge oncology magazine designed for oncologists and health professionals. It has flexible format, available both in print and online formats in the US and EU, ONCOLife is ...

New findings, published in Cellular and Molecular Gastroenterology and Hepatology, show that the transcription factor CREB ...

Birelentinib has received FDA Fast Track Designation for relapsed/refractory chronic lymphocytic leukemia (CLL) or small ...

This weekend, the Pan-Mass Challenge (PMC) unites more than 6,500 riders and 3,500 volunteers for its 46th ride, with the ...

The FDA has granted accelerated approval to Modeyso™ (dordaviprone) as the first treatment for recurrent H3 K27M-mutant ...